<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2018-01-17" updated="2020-01-02">
  <drugbank-id primary="true">DB13968</drugbank-id>
  <name>Plasma protein fraction (human)</name>
  <description>The plasma protein fraction human (PPFh) is defined as a sterile solution of proteins composed mainly of albumin and globulin derived from human plasma.[A32512] It is already reviewed under the category of biologics by the FDA where the processing, required tests, requirements and labeling are incorporated. This biologic should come from recovered plasma from whole blood or prepared source plasma. the final product should not include any type of additives. The composition of PPFh should be 5% of protein from which 83% should consist of albumin and no more of 17% should be globulin. It is also stated that no more than 1% of the total protein should be gamma globulin.[L2260] &#13;
&#13;
PPFh is a sterile, frozen solution of solvent/detergent treated human plasma.[L2262] The proteins in PPFh are stabilized with sodium caprylate and acetyltryptophan and it contains some electrolytes such as sodium, potassium and chloride.[L2261]</description>
  <cas-number/>
  <unii>6D53G0FD0Z</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A32512</ref-id>
        <pubmed-id>4104308</pubmed-id>
        <citation>Hink JH Jr, Pappenhagen AR, Lundblad J, Johnson FF: Plasma protein fraction (human). Physical and clinical properties after storage for 7-8 years. Vox Sang. 1970 Jun;18(6):527-41.</citation>
      </article>
      <article>
        <ref-id>A32517</ref-id>
        <pubmed-id>13367025</pubmed-id>
        <citation>KELLEY MB, ROBERTS S: Metabolism of plasma proteins in vitro. J Biol Chem. 1956 Oct;222(2):555-64.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L2260</ref-id>
        <title>FDA code of federal regulations</title>
        <url>https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=640&amp;showFR=1&amp;subpartNode=21:7.0.1.1.7.9</url>
      </link>
      <link>
        <ref-id>L2261</ref-id>
        <title>Dailymed</title>
        <url>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=679bbaf2-b082-5948-8400-ece5340eabc1</url>
      </link>
      <link>
        <ref-id>L2262</ref-id>
        <title>Dailymed</title>
        <url>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=998415d8-9bbe-e5b8-c3b0-3ba0344faacb</url>
      </link>
      <link>
        <ref-id>L2264</ref-id>
        <title>Octapharma</title>
        <url>http://www.octapharma.co.uk/fileadmin/user_upload/Octapharma_UK_New/OPL1402E.pdf</url>
      </link>
      <link>
        <ref-id>L2266</ref-id>
        <title>Octapharma monograph</title>
        <url>http://www.octapharma.ca/fileadmin/user_upload/octapharma.ca/20120502_PM_950_Octaplasma.pdf</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>PPFh is used as a replacement therapy in patients with complex deficiencies of coagulation factors such as coagulopathy. It is also used as a substitution therapy in emergency cases of factor deficiencies, for rapid reversal of the effects of oral anticoagulants or in dangerous hemorrhages during fibrinolytic therapy. PPFh can be used in therapeutic plasma exchange procedures including thrombotic thrombocytopenic purpura.[L2264]&#13;
&#13;
PPFh can be used in the treatment of shock where there is a predominant loss of plasma fluids and not red blood cells.[L2261]</indication>
  <pharmacodynamics>Preclinical studies were not performed as this product is exclusively human and any result in animals is not relevant. This factor creates the need for having very regulated manufacturing processes. From this control, the presence of two contaminants have been noticed (TNBP and Octoxynol). The administration of this two contaminants in rodents showed a very rapid elimination of TNBP with a terminal half-life of 20 min. TNBP was never found in urine and only traces were located in feces. In the case of octoxynol, it was not detected in plasma, urine or feces.[L2266]&#13;
&#13;
In humans, the use of PPFh is been reported to consistently regularize the level of all blood factors. In clinical trials was also observed a complete stop of abnormal bleeding.[L2266] The reported effect was sustained during 48 hours in the case of shock treatment.[L2261]</pharmacodynamics>
  <mechanism-of-action>PPFh acts by replacing the missing blood plasma factor in the patient. It is important to highlight that as a part of the manufacturing process, PPFh has to be completely virus inactivated.[L2266]</mechanism-of-action>
  <toxicity>Overdosage of PPFh can result in hypervolemia, pulmonary edema and or cardiac failure.[L2264] Studies regarding the mutagenic potential, effect in fertility and peri- and post-natal development, genotoxic potential and carcinogenic properties demonstrate that PPFh is an inactive product.[L2266]</toxicity>
  <metabolism>The different proteins constituting PPFh are metabolized as the normal endogenous proteins. From this thought, the liver seems to be the most important organ for the metabolism of plasma proteins. It is also known that globulins are more rapidly metabolized than albumin. Albumin is mainly metabolized by oxidation and used for energetic purposes.[A32517]</metabolism>
  <absorption>PPFh is administered always intravenously and thus, it is immediately available in the organism.[L2266]</absorption>
  <half-life>The registered clearance rate is reported to be in a range of 5-60 h. This value depends on the studied factor.[L2266]</half-life>
  <protein-binding>This pharmacokinetic property is not relevant.</protein-binding>
  <route-of-elimination>The different proteins constituting PPFh are metabolized as the normal endogenous proteins. Under this thought, after the corresponding metabolism, the proteins that constitute PPFh can be eliminated via feces, urine or expiration.[A32517]</route-of-elimination>
  <volume-of-distribution>The registered volume of distribution is reported to be of approximately 25-50 ml/kg. This value depends on the studied factor.[L2266]</volume-of-distribution>
  <clearance>The registered clearance rate is reported to be in a range of 0.6-7.9 ml.kg/h. This value depends on the studied factor.[L2266]</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Human plasma protein</synonym>
    <synonym language="english" coder="">Human plasma protein fraction</synonym>
    <synonym language="english" coder="">Human plasma proteins</synonym>
    <synonym language="english" coder="">Plasma protein fraction</synonym>
    <synonym language="english" coder="">Plasma protein fraction human</synonym>
    <synonym language="english" coder="">Plasma protein fraction,human</synonym>
  </synonyms>
  <products>
    <product>
      <name>Octaplas</name>
      <labeller>Octapharma USA Inc</labeller>
      <ndc-id/>
      <ndc-product-code>68982-954</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>11.5 g/200mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125416</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Octaplas</name>
      <labeller>Octapharma USA Inc</labeller>
      <ndc-id/>
      <ndc-product-code>68982-952</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>11.5 g/200mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125416</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Octaplas</name>
      <labeller>Octapharma USA Inc</labeller>
      <ndc-id/>
      <ndc-product-code>68982-953</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>11.5 g/200mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125416</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Octaplas</name>
      <labeller>Octapharma USA Inc</labeller>
      <ndc-id/>
      <ndc-product-code>68982-955</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-07-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>11.5 g/200mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125416</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Octaplasma</name>
      <labeller>Octapharma Pharmazeutika Produktionsges M B H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02270013</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-05-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Plasma Protein Fraction (human) Protenate</name>
      <labeller>Hyland, Division Of Baxter Healthcare Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00118354</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1963-12-31</started-marketing-on>
      <ended-marketing-on>2003-07-31</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Octaplas</name>
      <ingredients>Plasma protein fraction (human)</ingredients>
    </mixture>
    <mixture>
      <name>Octaplas</name>
      <ingredients>Plasma protein fraction (human)</ingredients>
    </mixture>
    <mixture>
      <name>Octaplas</name>
      <ingredients>Plasma protein fraction (human)</ingredients>
    </mixture>
    <mixture>
      <name>Octaplas</name>
      <ingredients>Plasma protein fraction (human)</ingredients>
    </mixture>
    <mixture>
      <name>Plasma Protein Fraction (human) Protenate</name>
      <ingredients>Plasma protein fraction (human)</ingredients>
    </mixture>
    <mixture>
      <name>Octaplasma</name>
      <ingredients>Plasma protein fraction (human)</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Albumins</category>
      <mesh-id>D000418</mesh-id>
    </category>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Biomimetic Materials</category>
      <mesh-id>D040761</mesh-id>
    </category>
    <category>
      <category>Blood Derivatives</category>
      <mesh-id/>
    </category>
    <category>
      <category>Blood Proteins</category>
      <mesh-id>D001798</mesh-id>
    </category>
    <category>
      <category>Blood Substitutes</category>
      <mesh-id>D001802</mesh-id>
    </category>
    <category>
      <category>Globulins</category>
      <mesh-id>D005916</mesh-id>
    </category>
    <category>
      <category>Hematologic Agents</category>
      <mesh-id>D006401</mesh-id>
    </category>
    <category>
      <category>Hemostatics</category>
      <mesh-id>D006490</mesh-id>
    </category>
    <category>
      <category>Plasma Substitutes</category>
      <mesh-id>D010952</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Serum Albumin</category>
      <mesh-id>D012709</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>11.5 g/200mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes>
    <ahfs-code>16:00.00</ahfs-code>
    <ahfs-code>20:28.16</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB13968.pdf?1523568486</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB13968.pdf?1523568193</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <sequences/>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Soluble</value>
      <source>'MSDS'</source>
    </property>
    <property>
      <kind>Boiling Point</kind>
      <value>&gt;100 ÂºC</value>
      <source>'MSDS'</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>7853</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>12888</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>